Figure 2 — Decitabine in combination with low-dose cytarabine, aclarubicin and G-CSF tends to improve prognosis in elderly patients with high-risk AML

Navigate

Research Paper|Volume 12, Issue 7|pp. 5792–5811

Decitabine in combination with low-dose cytarabine, aclarubicin and G-CSF tends to improve prognosis in elderly patients with high-risk AML

Back to articleFigure 2(2 of 8)

100%

Figure 2.Change in TP53^mut (A), FLT3^mut (B), and NPM1^mut (C) VAF in responders and non-responders to D-CAG with paired samples at diagnosis and after 1 cycle.

Figure 2 — Decitabine in combination with low-dose cytarabine, aclarubicin and G-CSF tends to improve prognosis in elderly patients with high-risk AML | Aging